Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Pharming Group N.V.

Pharming Group reports first quarter 2025 financial results and provides business update
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)
From Pharming Group N.V.
Via GlobeNewswire
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group to participate in March investor conference
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group to report fourth quarter and full year 2024 financial results on March 13
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group to participate in February investor conference
From Pharming Group N.V.
Via GlobeNewswire
Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
From Pharming Group N.V.
Via GlobeNewswire
Pharming announces public cash offer to the shareholders of Abliva AB
From Pharming Group N.V.
Via GlobeNewswire
Pharming announces positive topline data in pediatric clinical trial of leniolisib
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group to participate in November investor conference
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group reports third quarter 2024 financial results and provides business update
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group to report third quarter 2024 financial results on October 24
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
From Pharming Group N.V.
Via GlobeNewswire
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group to participate in September investor conferences
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group reports second quarter and first half 2024 financial results and provides business update
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group to report second quarter and first half 2024 financial results on August 1
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group to participate in June investor conferences
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group to participate in May investor conference
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group reports first quarter 2024 financial results and provides business update
From Pharming Group N.V.
Via GlobeNewswire
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
From Pharming Group N.V.
Via GlobeNewswire
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group to participate in April investor conferences
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group reports fourth quarter and full year 2023 financial results
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
From Pharming Group N.V.
Via GlobeNewswire
Pharming Group to participate in February investor conferences
From Pharming Group N.V.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.